In a recent video analysis, Chris Parry from Equity Guru brought to light some intriguing aspects of Medexus Pharmaceuticals (MDP.T), a player in the North American pharmaceutical industry known…
MDP.T
Hey y’all, Lucy Copperpot back for more analysis of Equity.Guru companies – this one is no longer on the client list, but I asked for permission to dig in…
Continuing out Core Story program, today’s exploration is a company we just can’t get enough of, Medexus Pharmaceuticals (MDP.T). CEO Ken D’Entremont has nailed his milestones the last 18…
Medexus Pharma (MDP.T) has made a significant mark in the pharmaceutical industry by focusing on bringing approved drugs from Europe and other jurisdictions to North America. Vishal Toora from…
Specialty pharmaceuticals is a unique niche in the pharma sector. Where companies like Eli Lilly pour billions into developing a drug candidate from scratch with the very real possibility…
Medexus Pharmaceuticals (MDP.T) has been a name synonymous with stellar growth and innovation. With its stock price climbing from $0.90 to $2.90 in a short period, it has captured…
When you come to a stock pick website like this and see a random story that ;predicts a company will have great revenue growth going forward, hey, I get…
Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF), a leading specialty pharmaceutical company, has been making waves with record annual revenues, a new credit agreement, and the acquisition of the Canadian…
Even though the COVID-19 pandemic posed challenges for healthcare and life sciences companies, Canada’s pharmaceutical industry continued to thrive, thanks to the government’s investments in pharma which buttressed the…
Specialty pharmaceuticals is a unique niche in the pharma sector. Where companies like Eli Lilly pour billions into developing a drug candidate from scratch with the very real possibility…